Genedrive MT-RNR1 ID Kit to detect genetic variation and protect hearing in babies: early value appraisal.

By HEOR Staff Writer

April 7, 2023

The Genedrive MT-RNR1 ID Kit has potential benefits in identifying babies at risk of hearing loss from aminoglycoside due to the MT-RNR1 m.1555A>G variant, allowing for alternative antibiotics to be used instead. However, managing the risk of early access is important, including ensuring timely antibiotics, avoiding unnecessary use of alternative antibiotics, and confirming positive results. The economic evidence suggests cost-effectiveness, but upfront costs may be high. Data should be generated in centers with babies from different ethnicities to promote equality.

Reference url

Recent Posts

Enhancing Efficiency in FAST-EU Clinical Trials: A New Era for Biomedical Research

By João L. Carapinha

December 1, 2025

Advancing EU Clinical Trial Efficiency Through FAST-EU Trials The FAST-EU clinical trials initiative, launched by a coalition of National Competent Authorities (NCAs) and Ethics Committees across the European Union/Europ...
Advancements in Continuous Glucose Monitoring for Type 2 Diabetes Management

By HEOR Staff Writer

November 27, 2025

Advancements in CGM for Type 2 Diabetes Management A recent JAMA Insights article, explores the integration of continuous glucose monitoring as a complementary tool to traditional hemoglobin A1c (HbA1c) an...
GLP-1RAs Psychiatric Care: Transforming Metabolic Management for Psychotropic Patients
Emerging Role of GLP-1 Receptor Agonists In psychiatric care, GLP-1RAs offer a promising approach for managing weight gain induced by psychotropic medications, as detailed in this